Literature DB >> 3995282

Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra.

A Y Deutch, S Y Tam, R H Roth.   

Abstract

The effects of stress on dopamine (DA) metabolism in the mesencephalic DA cell body areas and DA terminal field regions were examined. Both mild footshock stress and exposure to a neutral stimulus previously paired with footshock resulted in a selective increase in the levels of the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the prefrontal cortex as has been previously reported. Footshock stress also resulted in a slight but significant increase in DOPAC levels in the olfactory tubercles. DOPAC levels were selectively increased in the A10 cell body area (ventral tegmental area) but not A9 region (substantia nigra) by both footshock and the conditioned stress paradigm. These data indicate that the cell bodies of origin of the mesocortical dopaminergic system are activated by stress in contrast to those DA neurons innervating the striatum. It appears that mesocortical dopaminergic neurons exhibit different regulatory features than mesolimbic or nigrostriatal neurons.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995282     DOI: 10.1016/0006-8993(85)90134-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  38 in total

1.  Effects of immobilization stress and of a benzodiazepine derivative on rat central dopamine system.

Authors:  K Harada; K Noguchi; R Wakusawa
Journal:  J Anesth       Date:  1992-04       Impact factor: 2.078

2.  Age- and duration-dependent effects of MPTP on cortical serotonin systems.

Authors:  Twum A Ansah; Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2011-09-21       Impact factor: 3.046

3.  Dopamine in the nucleus accumbens modulates the memory of social defeat in Syrian hamsters (Mesocricetus auratus).

Authors:  C L Gray; A Norvelle; T Larkin; K L Huhman
Journal:  Behav Brain Res       Date:  2015-02-23       Impact factor: 3.332

4.  Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human.

Authors:  A J Bean; R Elde; Y H Cao; C Oellig; C Tamminga; M Goldstein; R F Pettersson; T Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

Review 5.  The effects of stress on central dopaminergic neurons: possible clinical implications.

Authors:  J M Finlay; M J Zigmond
Journal:  Neurochem Res       Date:  1997-11       Impact factor: 3.996

6.  Activation of forebrain dopamine systems by phencyclidine and footshock stress: evidence for distinct mechanisms.

Authors:  M B Bowers; M J Bannon; F J Hoffman
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease.

Authors:  Marcus C Ferguson; Tultul Nayyar; Ariel Y Deutch; Twum A Ansah
Journal:  Neuropharmacology       Date:  2010-03-31       Impact factor: 5.250

Review 8.  Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease.

Authors:  A Y Deutch
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Anxiolytic-like action of the 3-PPP enantiomers in the Vogel conflict paradigm.

Authors:  S Hjorth; A Carlsson; J A Engel
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

10.  Enhanced CRFR1-Dependent Regulation of a Ventral Tegmental Area to Prelimbic Cortex Projection Establishes Susceptibility to Stress-Induced Cocaine Seeking.

Authors:  Oliver Vranjkovic; Erik C Van Newenhizen; Michael E Nordness; Jordan M Blacktop; Luke A Urbanik; Jacob C Mathy; Jayme R McReynolds; Anna M Miller; Elizabeth M Doncheck; Tyler M Kloehn; Gwen S Stinnett; Clayton H Gerndt; Kyle D Ketchesin; David A Baker; Audrey F Seasholtz; John R Mantsch
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.